

Board of Directors

VENKATASATYANANDA	- Chairman - Non Executive Director
KOTESWARA RAO BOGGARAPU	- Non Executive & Independent
ANITHA MAHESH	- Non Executive & Independent
MANI MURUGADOSS RAO	- Non Executive & Independent
DHANROOP BETALA	- Non Executive & Independent

Registered Office

No.24,Railway Colony,
III Street, Aminjikarai,
Chennai- 600 029
Tamilnadu, India

Auditors

G. Sivaprakash
Chartered Accountant,
No.5, Fifth Cross Street,
West Shenoy Nagar, Chennai 600 030

Bankers/Financial Institutions

The Catholic Syrian Bank
Andhra Bank

Registrar and Share Transfer Agents

In house: Secretarial Department
INDO-AMERICAN ADVANCED PHARMACEUTICALS LIMITED
No.24,Railway Colony,
Iii Street, Aminjikarai,
Chennai- 600 029
Tamilnadu, India

Contents

- Notice
- Directors' Report
- Report on Corporate Governance
- Management Discussion and Analysis
- Auditors' Report
- Balance Sheet
- Profit & Loss Account,
- Notes on Accounts
- Cash Flow Statement
- Balance Sheet Abstract

NOTICE

NOTICE is hereby given that the **Twentieth** Annual General Meeting of the shareholders of the Company will be held on Wednesday, the 29th day of September 2012 at 10.30 A.M. at the registered office of the Company at No.24,Railway Colony, III Street, Aminjikarai, Chennai- 600 029, to transact the following business:

ORDINARY BUSINESS

1. To receive, consider and adopt the Audited Balance Sheet as at 31st March 2012 and the Profit & Loss Account for the year ended on that date and the reports of the Directors, and Auditors thereon.
2. To appoint a Director in place of Mrs. **ANITHA MAHESH**, who retires by rotation and being eligible, offers himself for reappointment.
3. To appoint a Director in place of Mr. **MANI MURUGADOSS RAO**, who retires by rotation and being eligible, offers himself for reappointment.
4. To appoint Statutory Auditor and fix his remuneration. Mr.G.Sivaprakash, Chartered Accountant, Chennai 600 030, the retiring Auditor of the Company is eligible for re-appointment and offer himself for re-appointment.

**By Order of the Board
For INDO-AMERICAN ADVANCED PHARMACEUTICALS LIMITED**

**B.V.S. Koteswara Rao
Managing Director**

Chennai, the 27th day of August, 2012

Registered Office

No.24,Railway Colony,
Iii Street, Aminjikarai,
Chennai- 600 029
Tamilnadu, India

NOTES

1. **A MEMBER ENTITLED TO ATTEND AND VOTE AT THE MEETING IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE ON A POLL INSTEAD OF HIMSELF AND A PROXY NEED NOT BE A MEMBER.PROXY TO BE VALID MUST BE DEPOSITED AT THE REGISTERED OFFICE OF THE COMPANY, NOT LATER THAN 48 HOURS BEFORE THE COMMENCEMENT OF THE MEETING. A PROXY FORM IS APPENDED WITH THE ADMISSION SLIP.**

2. An Explanatory Statement pursuant to Section 173(2) of the Companies Act, 1956 relating to the special business to be transacted at the meeting is annexed hereto.
3. The Register of Members and Share Transfer Books of the Company shall remain closed from Wednesday the September 26, 2012 to Friday the September 28, 2012 (both days inclusive) for the purpose of dividend entitlement which will be paid after approval of the shareholders in the ensuing Twentieth Annual General Meeting.
4. Members are hereby requested to send all corresponded concerning transfers, transmissions, subdivision, consolidation of shares or any other share related matters and/or change in address to the Company's Secretarial Department.
5. Members desiring to have any clarification on account are requested to write to the Company at an early date so as to enable the Company keep the information ready.
6. Members/ proxies should bring the attendance slip duly filled in for attending the meeting and corporate members are requested to send a duly certified copy of the Board resolution/ Power of Attorney authorizing their representative to attend and vote at the Annual General Meeting.
7. Members desirous of making a nomination in respect of their shareholding in the Company, as permitted under section 109A of the Companies Act, 1956, are requested to write to the Company's Registrar for the prescribed form.
8. Members who are holding shares more than one folio under physical form may approach the Company's Secretarial Department for consolidation with respective details.
9. Shareholders are requested to quote their Folio No. in all correspondence with the Company. All correspondences regarding shares of the Company should be addressed to "Secretarial Department", INDO-AMERICAN ADVANCED PHARMACEUTICALS LIMITED, No.24,Railway Colony, Iii Street, Aminjikarai, Chennai- 600 029.
10. Information pursuant to clause 49 of the listing agreement in respect of proposed appointment/ re-appointment of directors.

1	Name	Anitha Mahesh,
	Date of Birth	27-06-1976
	Date of Appointment	02-03-2012
	Qualifications	Graduate
	Expertise	She has associated with Companies and now having 5 Years of experience in the area of Finance General Management.
	Other Directorships <u>Name of the Company</u>	She is a Non Executive and Independent Director of the Company
	Committee Memberships, if any, with position	She is the member of Shareholders/Investors Grievance Committee of the Board of Directors of the Company.
	Shareholdings in the Company	Nil
	PAN	AZDPM6786D

2	Name	MANI MURUGADOSS RAO
	Date of Birth	21-04-1962
	Date of Appointment	02-03-2012
	Qualifications	Graduate
	Expertise	He has associated with Companies and now having 5 Years of experience in the area of Finance General Management.
	Other Directorships Name of the Company	Nil
	Committee Memberships, if any, with position	Nil
	Shareholdings in the Company	
	PAN	AABPR3180R

3	Name	B.V.S.Koteswara Rao
	Date of Birth	01-04-1955
	Date of Appointment	28-09-2011
	Qualifications	Under Graduate
	Expertise	He is the Founder of the Company and has been associated with the pharmaceutical Industries for more than three decades in the area of Marketing and Distribution.
	Other Directorships Name of the Company	Nil
	Committee Memberships, if any, with position	Nil
	Shareholdings in the Company	1,44,400
	PAN	ABVPB0500G

Important Communication to Members

The Ministry of Corporate Affairs has taken a "Green Initiative in the Corporate Governance" by allowing paperless compliances by the Companies and has issued circulars stating that service of notice / documents including Annual Report can be sent by email to its members. To support this Green Initiative of the Government in full measure, members who have not registered their e-mail addresses, so far, are requested to register their e-mail addresses to the "Secretarial Department", **INDO-AMERICAN ADVANCED PHARMACEUTICALS LIMITED, No.24,Railway Colony, III Street, Aminjikarai, Chennai- 600 029**

**By Order of the Board
For INDO-AMERICAN ADVANCED PHARMACEUTICALS LIMITED**

**B.V.S. Koteswara Rao
Managing Director**

Chennai, the 27th day of August, 2012
Registered Office
No.24,Railway Colony,
Iii Street, Aminjikarai,
Chennai- 600 029
Tamilnadu, India

DIRECTORS' REPORT TO THE MEMBER

Your Directors have great pleasure in presenting the **Twentieth** Annual Report together with Audited Accounts of the Company for the year ended 31st March 2012 and the Auditors' report thereon.

Financial Results

Particulars	(Amount In Rs.)	
	2011-2012	2010-2011
Total Income	20,78,110	24,03,191
Expenditure	52,48,709	24,78,766
Profit/(Loss) before depreciation and taxes	(31,70,599)	(75,575)
Less: Depreciation	Nil	3,96,281
Profit/(Loss) before Tax	(31,70,599)	(4,71,856)
Less: Provision for		
Current Tax	Nil	Nil
Deferred Tax	Nil	Nil
Fringe Benefit Tax	Nil	Nil
Profit/(Loss) after Tax	(31,70,599)	(4,71,856)
Add: balance brought forward from previous year	(2,86,99,633)	(2,82,27,777)
Available for appropriation	(3,18,70,232)	(2,86,99,633)
Balance carried to Balance sheet	(3,18,70,232)	(2,86,99,633)

Your Company has made a turnover of Rs.20, 78,110/- as compared Rs.24,03,191/- of previous year and has made a Loss after Tax of Rs.-31,70,599 /- as compared to Rs. -4,71,856/- in the previous year.

Business Performances and Outlook

The Company is in the business of trading of tablet, liquid orals, capsules and ointments under the allopathic system and capsules and liquid orals under the ayurvedic/ sidha systems. The Company's business involves significant investments in marketing for its operations. These expose the Company to risks in terms of timely and adequate availability of funds at competitive rates to finance its growth. The Company hopes with better network it can improve the performance in the ensuing year.

Fixed Deposits

Your Company has not accepted any deposits from public or its employee during the year under review.

Dividend

In view of loss, your directors have not recommended any dividend during the year under report.

Subsidiaries / Joint Ventures

There are no Subsidiaries and Joint Venture Company.

Insurance

All insurable interests of the Company including, buildings, furniture and fixtures and other insurable interest are adequately insured.

STATUTORY STATEMENTS

Conservation of Energy, Technology Absorption and Foreign Exchange Earnings and Outgo

Pursuant to Section 217 (1) (e) of the Companies Act, 1956 read with Companies (Disclosure of Particulars in the Report of Board of Directors) Rules, 1988 the required particulars are furnished below.

Conservation of energy:

Energy conservation continues to receive utmost priority and the Company monitors energy costs and reviews the consumption of energy on a regular basis. The Company wherever necessary also initiates appropriate measures to reduce consumption of electricity, including using Generator. It has closely monitored power consumption and running hours on day to day basis thus resulting in optimum utilization of energy

Technology Absorption

The relevant particulars relating to technology absorption in terms of Rule 2 of the Companies (Disclosure of Particulars in the Report of the Board of Directors) Rules, 1988 is not applicable as such the Company does not have any significant manufacturing operations.

Research and Development:

Not Applicable

Foreign exchange earnings and outgo:

There are no foreign exchange earning and outgo during the year under review.

Particulars of Employees

During the year under review, there were no employees covered under Section 217(2A) of the Companies Act, 1956 read with the Companies (Particulars of Employees) Rules, 1975.

The Board of Directors wishes to express its appreciation to all the employees of the Company for their outstanding contribution to the operation of Company during the year.

Directors' Responsibility Statement

Pursuant to the requirement u/s 217(2AA) of the Companies Act, 1956 with respect to Directors' Responsibility Statement your Directors to the best of their knowledge and belief confirm that:

- (i) in the preparation of the annual accounts, the applicable Accounting Standards and given proper explanation relating to material departure;
- (ii) we have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give true and fair view of the state of affairs of the Company at the end of the financial year and of the Loss of the Company for that period;

- (iii) we have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act so as to safeguard the assets of the Company and to prevent and detect fraud and other irregularities; and
- (iv) We have prepared the annual Accounts on a going Concern basis.

Internal Controls and their Adequacy:

The internal control systems are commensurate to the size of the operation of the Company. Whenever it is required, the systems and procedures are upgraded to suit the changing business needs.

Statement Pursuant to Listing Agreement

The company's securities are listed with Bombay Stock Exchange, however trading of the securities has been suspended on non compliance of certain clauses of the Listing Agreement. However, the trading of securities has been resumed from May 4, 2012 after compliance with Stock Exchange regulations.

Code of Corporate Governance

A detailed report on Corporate Governance as updated with the particulars of this Financial year, as per the directions from SEBI is annexed to this report (Annexure A') together with Report of the Auditors on the compliance with the said Code and a report of Management discussion and Analysis is also annexed separately.

Directorate

The Company is managed by Mr. B.V.S. Koteswara Rao, Managing Director under strict supervision of the Board of Directors.

In compliance with the provisions of the Companies Act, 1956 in accordance with the Article 121(b) of the Company's Articles of Association, Mr. Anitha Mahesh and Mr. **MANI MURUGADOSS RAO**, retire at this Annual General Meeting and being eligible, offers themselves for re-appointment.

Brief resume of the Directors, seeking re-appointment, nature of their expertise as stipulated under clause 49 of the listing agreement with *inter alia* the Bombay Stock Exchange Limited, is appended to the notice convening the Annual General Meeting.

Compliance Certificate

Compliance Certificate issued by a Practicing Company Secretary is attached herewith and forming part of this report

Auditors and Auditors Report

The retiring auditors, Mr.G.Sivaprakash, Chartered Accountant, No.5, Fifth Cross Street, West Shenoy Nagar, Chennai 600 030, has expressed willingness to continue in office, if appointed. He has furnished to the Company a certificate of his eligibility for appointment as auditor, pursuant to section 224 (1B) of the Companies Act, 1956.

The Audit committee and the Board of Directors recommend the re-appointment of Mr.G.Sivaprakash, Chartered Accountant, Chennai as Auditor for a further period of one year and to fix his remuneration.

The Auditors Report to the Members does not contain any qualification or adverse remarks.

Disclosures of Particulars of Constituting “Group” pursuant to Regulation 3(1)(e) of the SEBI(Substantial Acquisition of Shares & Takeovers) Regulations, 1997.

Pursuant to an information from the promoters, the name of the promoters and entities comprising group as defined under Monopolies and restrictive Trade Practice (MRTP) Act, 1969, are as under for the purpose of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 1997 : V. Koteswara Rao, BVS Koteswara Rao, BSS Prasad Rao Kiran Kumar, B.V. Ramalakshmi, V.S ubbamma, B. Vijayalakshmi, V. Subba Rao, V. Murali Krishnan, V. Sathya Lakshmi, V. Swarnalatha, T. Ramadevi and T. Ramakrishnan

Dematerialization of Shares

The Company propose to get its Equity Shares admitted for dematerialization with National Securities Depository Limited (NSDL and Central Depository Services (India) Limited (CDSL) and will intimate the same to all shareholders once International Securities Identification Number (ISIN) got allotted. Considering the advantages of scrip less trading, shareholders are requested to consider dematerialization of their shareholding so as to avoid inconvenience in future.

Acknowledgement

The Directors place on record their appreciation for the sincere and whole hearted co-operation extended by all concerned, particularly Securities & Exchange Board of India, Stock Exchanges, company’s bankers, Municipal authorities, Government of Tamilnadu, Central Government, suppliers, clients and staff and look forward to their continued support. The Directors also thank the Shareholders for continuing their support and confidence in the Company and its management.

**For and Behalf of the Board of Directors
For INDO-AMERICAN ADVANCED PHARMACEUTICALS LIMITED**

**B.V.S. Koteswara Rao
Managing Director**

**Anitha Mahesh
Director**

Chennai, the 27th day of August, 2012

ANNEXURE – ‘A’

TO THE TWENTIETH ANNUAL REPORT OF THE BOARD OF DIRECTORS REPORT ON CORPORATE GOVERNANCE

INDO-AMERICAN ADVANCED PHARMACEUTICALS LIMITED is complying with the mandatory requirements of the code of Corporate Governance introduced by the SEBI and incorporated in Clause 49 of the Listing Agreement in all material respect.

The Basic philosophy of the company towards Corporate Governance is to protect and enhance the long term value of all the stakeholders – shareholders, clients, creditors and employees. The Company is committed to achieve these objectives within regulatory frame work through transparency in dealings.

Board of Directors

The Board of Directors of the Company comprises of a one Managing Director and three Non executive & independent Directors. The Board members posses requisite skills, experience and expertise required that are required to take decisions, which are in the best interest of the Company.

Mr. B.V.S. Koteswara Rao, is the Managing Director of the Company. He works under the direction, control and supervision of the Board of Directors and it meets at regular intervals. Policy formulation, evaluation of performance and control functions vest with Board

The Composition of Board, attendance of each Director at the Board Meetings held during the year under review as well as in the last Annual General Meting and number of other Directorship/ Committee memberships held by them are as follows:-

Name of Director	Designation and Category	No. of Board Meetings in the Year		Attendanc e Of Last AGM	Number of directorships held in the Indian Companies (including this Company)	Number of Board Committee memberships Held in other companies
		Held	Attended			
V.Koteswara Rao	Chairman - Non Executive Director	05	05	Yes	1	Nil
B.V.S.Koteswara Rao	Managing Director	05	05	Yes	2	Nil
T. Rama Devi	Non Executive Director	05	05	Yes	1	Nil
V.Venkatasubbama	Non Executive Director	05	05	Yes	1	Nil
S.R.Krishna	Non Executive & Independent	05	05	Yes	1	Nil
B.Suresh Babu	Non Executive & Independent	05	05	Yes	1	Nil
Parthasarathi Ray	Non Executive & Independent	05	05	Yes	1	Nil

The requisite information as prescribed under Clause 49 of the Listing Agreement is placed before the Board from time to time and is generally provided as part of the Agenda papers of the Board Meeting and /or is placed at the table during the course of the meeting.

The Board of Directors met Five (05) times on 06-04-2011, 06-07-2011, 05-10-2011, 06-01-2012, and 08-02-2012 in respect of which meetings proper notices were given and the proceedings were properly recorded and signed, in the Minutes Book maintained for the purpose.

The Annual General Meeting for the financial year ended on 31-03-2012 was held on 29-09-2012 by giving due notice to the members of the Company and the resolutions passed there at were recorded in Minutes Book maintained for the purpose.

Equity Shares held by the Director :-

Name of the Directors	No. of Equity Shares as on 31st March 2012
B.V.S. Koteswara Rao	1,44,400

There are no other shares or convertible instruments held by any other directors

Information about the Directors proposed to be appointed/ re-appointed required to be furnished pursuant to Clause 49 of the listing agreement with the Stock Exchanges is forming part of the notice of the Nineteenth Annual General Meeting to the shareholders of the Company

Audit Committee

Section 292A of the Companies Act, 1956 is applicable to the company.

Terms of reference

Your Company has an independent Audit Committee. The composition procedures, powers and role/functions of the audit committee constituted by the company comply with the requirements of Clause 49 of the Listing Agreement.

The terms of reference of the Audit Committee included the following:

- Overseeing the company's financial reporting process and the disclosure of its financial information.
- Recommending appointment and removal of the external auditor, fixing of audit fees and approving payments for any other service.
- Reviewing with management the quarterly, half yearly and annual financial statement with primary focus on accounting policies and practices, compliance with accounting standards, any related party transaction and stock exchange and legal requirements concerning financial statements.
- Reviewing adequacy of internal control systems in order to have the effective use and safeguard of resources and compliance with statutes polices and procedures and ensure compliance of internal control systems and reviewing the company's financial and risk management policies.
- Reviewing reports furnished by the Statutory Auditors and ensuring suitable follow up thereon.

The un-audited/ audited financial results of the Company are also specifically reviewed by the Audit Committee before these are submitted to the Board for approval. Minutes of each audit Committee meetings are placed before the Board for information.

Composition and Attendance

The Company has an Audit Committee of the Board consisting of three “Non-Executive & Independent Directors “as members as detailed below and all members have adequate financial and accounting knowledge, who met Five (05) times during the year 08-04-2011, 08-07-2011, 08-10-2011, 08-01-2012, and 30-03-2012 during the year and the details of the number of meetings held and attendance record of the members are as follows:

Name of Directors	Status and Category	No. of Meetings	
		Held	Attended
Parthasarathi Ray	Chairman Non Executive & Independent	04	04
S. R. Krishna	Member Non Executive & Independent	04	04
B. Suresh Babu	Member Non Executive & Independent	04	04

All the members, including the Chairman have adequate financial knowledge. The Audit Committee reviews the Un-audited/audited quarterly, half yearly financial results with the management before being submitted to the Board for its consideration and approval. The Chairman of the Audit Committee is always present at the Annual General meeting.

Remuneration Committee

Your Company has constituted a Remuneration Committee under the chairmanship of Mr. Dhanroop Betala. The Remuneration committee consisting of Mr. Dhanroop Betala, Mr. Anitha Mahesh and Mr. B.V.S. Koteswara Rao to decide the structure of the Executive Director’s Remuneration.

Executive Director

The Company has a Managing Director. There was no revision to the salary of the Managing Director during the year under review. The remuneration paid to him during the period 01-04-2011 to 31-03-2012 was as under

(Amount in Rs.)

Name and Designation	Period	Salary	Perquisites	Total
B.V.S. Koteswara Rao	01-04-2011 to 31-03-2012	60,000/-	NIL	60,000/-

Mr. B.V.S. Koteswara Rao, was not paid any sitting fees for the Board meetings or of any Committees of the Board attended by him.

Non-Executive Director

Non-Executive Directors of the Company are remunerated by way of sitting fees for the meetings of the Board/Committees of the Board attended by them. There was no other payment to the Non-Executive Directors.

None of the non-executive directors has pecuniary relationship with company, its promoters, management.

Shareholders/ Investor's Grievance Committee

The Investors Grievance Committee of the Board oversees share transfers and monitor investors grievances such as complaints on transfer of shares, non receipt of balance sheet, non receipt of declared dividends etc., and redressal thereof, within the purview of the guidelines setout in the listing agreement.

Composition and Attendance

The Shareholders/Investors' Grievance Committee consist of the following Directors

Name	Status	Position held
Anitha Mahesh	Non Executive and & Independent	Member
Dhanroop Betala	Non Executive and & Independent	Member
B.V.S. Koteswara Rao	Managing Director	Chairman

Mr. B.V.S. Koteswara Rao is the Compliance officer. The Company use to give a detailed report on steps taken by it to the Committee to specifically look into redressing shareholders and investor's complaint, break up of the nature of complaints received including number of complaints not resolved to the satisfaction of the complainants. Additionally details of communication received from agencies like Stock Exchanges/SEBI/ Ministries of Companies Affairs were placed with an explanation as to how such communication were responded to and within how may days/ weeks.

The Company has not received any investors' compliant during the year.

General Body Meetings:

The details of the Annual General Meetings held during the last three years are as follows: -

Financial Year	Location	Date	Time
2008-2009	No.24,Railway Colony, III Street, Aminjikarai, Chennai- 600 029,	September 30, 2009	3.30 PM
2009-2010	No.24,Railway Colony, III Street, Aminjikarai, Chennai- 600 029,	September 30, 2010	3.30 PM
2010-2011	No.24,Railway Colony, III Street, Aminjikarai, Chennai- 600 029,	September 28, 2010	3.30 PM

All the resolutions including the special resolutions, if any as set out in the respective notices were passed by the shareholders.

No resolution is proposed to be passed at the forthcoming Annual General meeting through postal ballot.

Disclosure made by the senior managerial personnel to the Board

During the year no material transaction has been entered into by the Company with the Senior Managerial personnel where they had or were deemed to have had personal interest that may have potential conflict with the interest of the Company.

Disclosures on materially significant related party transactions

The details of the transaction with related parties or others if any as prescribed in the listing agreement are being placed before the Audit committee from time to time There were no other transactions of material nature has been entered into by the Company with related parties (i.e.) Directors or Management, or relatives that had potential conflict with the interest of the Company at large in the financial year ended March 31, 2012.

Disclosure of Accounting Treatment

No treatment different from that prescribed in an Accounting Standard have been followed by the Company

Risk Management

In order to ensure that management controls risk through means of properly defined frame work a report on Risk Management and minimize on procedures as received from the Individual functional heads of the Company is placed before the Board of Directors of the Company.

Code of Conduct for the Directors and Senior Management Personnel

The Company has laid down a Code of Conduct (Code) for all the Board Members and Senior Management Personnel of the Company. The Code is also posted on the Website of the Company. All Board Members and Senior Management Personnel have affirmed their compliance with the Code for the financial year ended 31st March, 2012. A declaration to this effect signed by Mr. B.V.S. Koteswara Rao, Managing Director of the Company forms part of this report.

CEO/CFO Certification

In terms of Clause 49 (V) of the Listing Agreement, the Certificate duly signed by Mr. B.V.S. Koteswara Rao, Managing Director was placed before the Board of Directors along with financial statement for the financial year ended March 31, 2011 at its meeting held on 26th day of August, 2012.

Proceeds from Public/ Rights/ Preferential Issues, etc,

The Company does not have any unutilized money raised through Public/ Rights/ Preferential Issues, etc.

Compliances by the Company

The Board of Directors is periodically reviewing the Compliance Reports of the Laws applicable to the Company and the Company initiates requisite actions for strengthening of its statutory compliance procedures as may be suggested by the Board from time to time.

Details of non-compliances with regard to Capital Market

The Company equity shares are suspended due to non compliance of listing agreement and apart from the same there were no instances of non-compliance by the Company on any matter related to capital markets during the last three years. Hence there was no penalty, strictures imposed by SEBI/Stock Exchange or any other statutory/local authorities against the Company.

The Management Discussion and Analysis report forms part of the Annual Report.

General Shareholder's Information

Financial Calendar (Tentative)

Financial year	April 1, 2011 to March 31, 2012(Subject to Change)
First Quarter Result	
Second Quarter Result and Half-yearly Result	By fourth week of July 2011
Third Quarter Result	By fourth week of October 2011
Fourth Quarter Result	By fourth week of January, 2012
Annual Result (Audited)	By fourth week of April, 2012
Annual General Meeting	Within 6 months of the close of the financial year In accordance with Section 166 of the Companies Act, 1956.
Dates of book closure	26 th September, 2012 to 28 th September, 2011. (Both days Inclusive)
Venue and other details of the Annual General Meeting	No.24,Railway Colony, III Street, Aminjikarai, Chennai- 600 029, Wednesday, the 29 th day of September 2012 at 3.30 PM
Dividend Payment Date	N.A
Listing on Stock Exchange and Stock Code The Equity Shares of Rs.10/- each are Listed at	Bombay Stock Exchange, Madras Stock Exchange, Hyderabad Stock Exchange and Cochin Stock Exchange (Annual Listing for fee for the year 2010-2011) is being paid. Scrip Code 531689 and ID : INAMPHA

Stock Market Data

No shares were traded during the financial year due to suspension of Scrip for trading on BSE and accordingly Stock Market data for the period April 01 2011 to March 31, 2012 and Graphical representation of volume of Shares of during April 01 2011 to March 31, 2012 are not provided.

Dematerialization of Shares and Liquidity

The Company propose to get admitted its Equity Shares for dematerialization with National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL) and will intimate the same to all shareholders once International Securities Identification Number (ISIN) got allotted. Considering the advantages of scrip less trading, shareholders are requested to consider dematerialization of their shareholding so as to avoid inconvenience in future. The Shares of your Company are under compulsory demat settlement mode and can be traded only in the demat form.

Registrar and Share Transfer Agents (RTA)

The Company has appointed Registrar and Share Transfer Agents (RTA) in Pursuant to newly introduced regulations 53A of the Securities and Exchange Board of India (Depositories & Participants) Regulations, 1996, The name of the RTA is "CAMEO CORPORATE SERVICES LIMITED" their complete address is as under

CAMEO CORPORATE SERVICES LIMITED

No.1,Club House Road,
Subramanian Building, Chennai- 600 002
Tel : 91- 44 – 28460390. Email ID : cameo@cameoindia.com

All requests received by the Company/ RTA for dematerialisation/ re-materialisation, transfers, transmissions, subdivision, consolidation of shares or any other share related matters and/or change in address are disposed off expeditiously.

Distribution of Share holding as on 31-03-2012

S. No	Category	No of Holders	% of Holders	No of Shares
1	Upto 500	2570	77.25	1286200
2	501 - 1000	109	3.27	89800
3	1001 - 2000	104	3.12	191500
4	2001 - 3000	295	8.79	780800
5	3001 - 4000	114	3.33	405600
6	4001 - 5000	78	2.28	372400
7	5001 - 10000	25	0.81	222500
8	10001 and Above	37	1.14	1660400
	Total	3332	100	5009200

As required under Circular No.D&CC/FITC/CIR-16/2004 dated 31st December, 2004 issued by the Securities and Exchange Board of India and amended thereafter, the Company has appointed a Practicing Company Secretary to do the Secretarial Audit and the report was placed before the Board and sent forthwith to Stock Exchanges for their information and record.

Categories of Shareholdings as on March 31, 2012

	Category	No. of shares held	Percentage of shareholding
A	Promoter's holding		
1.	Promoters* - Indian Promoters	920400	18.37%
2.	Persons acting in concert #	0	0
	Sub-Total	920400	18.37%
B.	Non-Promoters Holding	0	0
3.	Institutional Investors	0	0
a.	Mutual Funds and UTI	0	0
b.	Banks, Financial Institutions, Insurance Companies (Central / State Govt. Institutions / Non-government Institutions)	0	0
c.	FII's	0	0
	Sub-Total	0	0
4.	Others		
a.	Private Corporate Bodies	0	0
b.	Indian Public	4088800	81.63%
	Sub-Total	4088800	81.63%
	GRAND TOTAL...	5009200	100.00%

Company Registration Details

The Company is registered in the State of Tamil Nadu. The Corporate Identity Number (CIN) allotted to the Company by the Ministry of Corporate Affairs (MCA) is L24231TN1992PLC022562

Legal Proceedings:

There is no legal proceeding pending against the Company.

Plant Location

Gauravaram Village,
Kavali (M), Nellore District,
Andhra Pradesh.

The Company has not issued any GDRs/ADRs/ Warrants/Convertible Instruments.

Address for Communication

INDO-AMERICAN ADVANCED PHARMACEUTICALS LIMITED

No.24,Railway Colony,
III Street, Aminjikarai,
Chennai- 600 029
Tamilnadu, India

Tel : 91- 44 – 42555528. Email ID : kiranbvs@yahoo.com

In terms of clause 47(f) of the Listing Agreement of Stock Exchanges, investors may please use kiranbvs@yahoo.com as email id for redressal of investor request/complaint.

MANAGING DIRECTOR'S DECLARATION ON CODE OF CONDUCT

As required by clause 49 of the Listing Agreement the Managing Director's declaration on code of conduct is as under.

I, **B.V.S. Koteswara Rao**, Managing Director of the Company declare that all the Board members and senior Management of the Company have affirmed compliance with the code of conduct

B.V.S. Koteswara Rao
Managing Director

Chennai, the 26th day of August, 2012

COMPLIANCE CERTIFICATE ON CORPORATE GOVERNANCE FROM AUDITORS

The Certificate dated 26th day of August 2012, obtained from Statutory Auditors of the Company Mr.G.Sivaprakash, Chartered Accountant, Chennai, confirming compliance with the Corporate Governance requirements under Clause 49 of the Listing Agreement, is annexed hereto.

For and on behalf of the Board
For INDO-AMERICAN ADVANCED PHARMACEUTICALS LIMITED
S/d-
B.V.S. Koteswara Rao
Managing Director

Chennai, the 27th day of August, 2012

MANAGEMENT DISCUSSION AND ANALYSIS REPORT:

The management of **Indo-American Advanced Pharmaceuticals Limited (IAAPL)** presents below its analyses and performance of the Company for the year 2011-12 and an outlook for the future. The report conveys expectations on future performance based on an assessment of the current business environment. These could vary based on future developments.

Industry's Structure and Development:

The global pharmaceutical industry is expected to grow by 6% to 7% in 2011 to reach USD 1015 billion compared to 5 to 7% in 2010. In this growth the emerging markets pharmaceutical growth is at a higher pace of 17% in 2011 to reach USD 180 billion. The major emerging markets are China, Brazil, Russia, India, Mexico, Turkey, Argentina, Indonesia, Thailand, South Africa and Egypt. Greater Government spending on Health Care and broader public and private Health Care funding are likely to be the key drivers of growth for many of the Pharmaceutical Emerging Markets. China, the world's 3rd largest pharmaceutical market is predicted to grow by 25% to 27% to more than USD 50 billion in 2011 while the US is likely to grow at 3% to 5%.

India has emerged as one of the leading economies when it comes to opportunities in the pharmaceutical sector. The Indian Pharmaceutical market is projected to grow to about USD 20 billion by 2015, as against USD 6.3 billion in 2005. Currently, the Indian pharmaceutical industry is ranked fourth in terms of volume and fourteen in terms of value in the global pharmaceutical market. The industry has attained self-reliance in the production of formulations, and produces almost 70% of the bulk drug requirements of the country. India is also one of the major producers of generic drugs in the world. Indian Pharmaceutical Industry has not been affected much by the global slow down, largely because of the cost advantages in medicine production and due to their long term contracts, especially the generic manufactures, with their preferred suppliers. During the year 2010-11, the performance of the export front has been good to reach USD 6 billion. The rising middle and upper class who can afford high quality health care and the widespread adoption of Health Insurance Products, which will enable a large proportion of the population to access medical treatments, are expected to drive the Indian Pharmaceutical Market in the foreseeable future. In addition, significant economic growth rates, favourable demographics, and new intellectual property protection laws would provide future impetus to the industry.

Business Outlook

The Company is in the business of trading of tablet, liquid orals, capsules and ointments under the allopathic system and capsules and liquid orals under the ayurvedic/ sidha systems. The Company's business involves significant investments in marketing for its operations. These expose the Company to risks in terms of timely and adequate availability of funds at competitive rates to finance its growth.

Regulatory and Legal Risks

IAAPL is exposed to regulatory and legal risks in carrying out its business. These include legal proceedings on properties, customer complaints, noncompliance of regulations including environmental regulations and those pertaining to the hospitality sector. The

company has systems and controls in place to mitigate these risks and minimize instances of non-compliance.

Risk Management Systems

The Company's risk management strategy is based on a clear understanding of various risks, disciplined risk assessment and measurement procedures and continuous monitoring. The policies and procedures established for this purpose are continuously benchmarked with best practices.

Internal Control System

The Company has adequate internal control procedures commensurate with its size and nature of the business. These business control procedures ensure efficient use and protection of the resources and compliances with the policies, procedures and status. The internal control system provides for well-documented policies, guidelines, authorizations and approval procedures.

Discussion on Financial performance with respect to operational performance:

Your Company has made a turnover of Rs. 20,78,110 /- as compared Rs. 24,03,191/- of previous year and has made a Loss after Tax of Rs.31,70,599 /- as compared to Rs.4,71,856/- in the previous year.

Material developments in Human Resources /Industrial Relations front, including number of people employed.

There have been no material changes / developments in Human relations front.

**For and Behalf of the Board
For INDO-AMERICAN ADVANCED PHARMACEUTICALS LIMITED**

**B.V.S. Koteswara Rao
Managing Director**

Chennai, the 27th day of August, 2012

G. Sivaprakash

AUDITOR'S CERTIFICATE

To,
The Members of Indo-American Advanced Pharmaceuticals Limited

We have examined the compliance of conditions of Corporate Governance of Indo-American Advanced Pharmaceuticals Limited for the year ended 31st March 2012 as stipulated in clause 49 of the Listing Agreement of the said Company with Stock Exchange(s).

The compliance of conditions of Corporate Governance is the responsibility of the Management. Our examination was limited to procedures and implementation thereof, adopted by the Company for ensuring the compliance of conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

In our opinion and to the best of our information and according to the explanations given to us, we certify that the Company has broadly complied with the conditions of Corporate Governance as stipulated in the above mentioned Listing Agreement.

We state that no investor grievance(s) against the Company is/are pending exceeding one month as per records maintained by the Shareholders' Committee.

We further state that such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the management has conducted the affairs of the Company.

Place: Chennai
Date: 27.08.2012

For G. Sivaprakash
Chartered Accountant

G. Sivaprakash
Proprietor
Membership No. 200/24556

G. Sivaprakash

AUDITOR'S REPORT

To the Members of **INDOAMERICAN ADVANCED PHARMACEUTICALS LIMITED**

I have audited the attached Balance Sheet of **INDO AMERICAN ADVANCED PHARMACEUTICALS LIMITED** as at 31ST March, 2012 and also the Profit and Loss Account for the year ended on that date annexed thereto. These financial statements are the responsibility of the Company management. My responsibility is to express an opinion on the financial statements based on my audit.

1. I conduct my audit in accordance with auditing standards accepted in India. These standards require that I plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosing in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management as well as evaluating the overall financial statement presentation. I believe that my audit provides a reasonable basis for my opinion.
2. As required by the Manufacturing and Other Companies (Auditor's Report) Order, 1988 issued by the Central Government of India in terms of sub-section (4A) of Section 227 of Companies Act, 1956, I enclose in the Annexure a statement on the matters specified in paragraphs 4 and 5 of the said Order.
3. Further My comments in the Annexure referred to above, I report that :
 - (i) We have obtained all the information and explanations which, to the best of my knowledge and belief, were necessary for the purpose of my audit.
 - (ii) In my opinion, proper books of accounts as required by law have been kept by the Company so far as appears from my examination of these books.
 - (iii) The Balance Sheet and Profit and Loss Account is dealt with by this report are in agreement with the books of account.
 - (iv) In my report, the Balance Sheet and Profit & Loss Account dealt with by this report comply with the accounting standards referred to in sub section (3C) of section 211 of the Companies Act.
 - (v) On the basis of written representations received from the directors as on 31st March 2012, and taken on record by the Board of Directors, I report that none of the directors are disqualified as on 31st March, 2012 from being appointed as a director in terms of clause (g) of sub-section (1) of Section 274 of the Companies Act, 1956.

G. Sivaprakash

- (vi) In my opinion and to the best my information and according to the Explanations given to me the Balance Sheet and Profit and Loss Account give a true and fair view in conformity with the accounting principles generally accepted in India.
- a. In the case of the sheet, of the state of affairs of the Company as at 31st March 2012 and
 - b. In the case of the Profit and Loss Account of the loss for the year ended on that date.

Place: Chennai
Date: 27.08.2012

For G. Sivaprakash
Chartered Accountant

G. Sivaprakash
Proprietor
Membership No. 200/24556

G. Sivaprakash

ANNEXURE REFERRED TO IN PARAGRAPH 2 OF MY REPORT OF EVEN DATE TO THE MEMBERS OF INDO AMERICAN ADVANCED PHARMACEUTICALS LIMITED ON THE ACCOUNTS AS AT AND FOR THE YEAR ENDED 31ST MARCH, 2012.

1. The Company generally maintained proper records showing full particulars including quantitative details and location of its Fixed Assets. The management has physically verified the Fixed Assets at reasonable intervals and no material discrepancies are reported to have been observed on such verification as compared to book records.
2. None of the Fixed Assets of the Company have been revalued during the year.
3. The stocks, finished goods, stores and spares, raw materials etc., have been physically verified by the management at reasonable intervals during the year.
4. The Company has not taken any loans, secured or unsecured from the companies, firms or other parties listed in the register maintained under section 301 of the Companies Act, 1956. I am informed that there is no Company under the same management as defined under section 370 (1B) of the Companies Act, 1956.
5. The Company has not granted any loans, secured or unsecured, to the companies, firms or other parties listed in the register maintained under section 301 of the Companies Act, 1956. I am informed that there is no Company under the same management as defined under section 370 (1B) of the Companies Act, 1956.
6. In my opinion and according to the information and explanations given to me, there are adequate internal control procedures commensurate with the size of the Company and the nature of the business with regard to purchase of spares and stores, raw materials, plant and machinery equipment and other assets and for the sale of goods.
7. According to the information and explanations given to me, there is no transactions of purchase of goods and sale of medicines made in pursuance of contracts or arrangements entered in the register maintained under Section 301 or more during the year in respect of each party have been made at prices, which were reasonable having regards to the prevailing market prices for such medicines or prices at which the transactions for similar goods have been made with other parties.
8. As informed to me, the Company generally has a reasonable system of determination of unserviceable or damage stores and spares, raw materials, and finished goods, and adequate provision for the loss arising on such items has been made during the year and review.

9. The Company has not accepted any deposited from the public within the meaning of Section 58A of the Companies Act, 1956 and the rules framed thereunder.
10. In my opinion, the Company has maintained reasonable records for the sale of disposal of its realizable scrap.
11. The Company is yet to install an internal Audit System commensurate with the size and nature of business.
12. 12.According to the information and explanations given to us no personal expenses of employees of directors have been charged to revenue account, other than those payable under contractual obligations or in accordance with generally accepted business practice.
13. I have been informed that the Central Government has not prescribed maintenance of cost records under section 209 (1) (d) of the Companies Act 1956 for any of the products of the Company.
14. The Company does not have any Provident Fund Scheme.
15. The Company has generally been regular in depositing Employees State Insurance with appropriate authorities in time.
16. According to the information and explanation given to me and the books records examined by me, there is no undisputed amounts payable in respect of income-tax, Wealth Tax, Sales Tax, Customs duty and Excise duty outstanding as at 31st March 2012 for a period exceeding six months from the date it became payable.
17. The Company is not a sick industrial Company as defined in the sick industrial Companies (Special provisions) Act, 1956.

Place: Chennai
Date: 27.08.2012

For G. Sivaprakash
Chartered Accountant

G. Sivaprakash
Proprietor
Membership No. 200/24556

INDO-AMERICAN ADVANCED PHARMACEUTICALS LTD

BALANCE SHEET AS AT 31st MARCH, 2012

(All amount in Rupees except Share data and unless otherwise stated)

PARTICULARS	Note No.	31.03.2012	31.03.2011
		₹	₹
EQUITY AND LIABILITIES			
SHAREHOLDERS' FUNDS			
Share Capital	2.1	37,580,000	37,580,000
Reserves and Surplus	2.2	(31,870,232)	(28,699,633)
		5,709,768	8,880,367
SHARE APPLICATION MONEY PENDING ALLOTMENT		765,633	765,633
NON-CURRENT LIABILITIES			
Deferred Tax Liabilities (Net)		-	-
		-	-
CURRENT LIABILITIES			
Other Current Liabilities	2.3	634,991	760,821
Short-Term Provision		-	-
		634,991	760,821
TOTAL		7,110,392	10,406,821
ASSETS			
NON- CURRENT ASSETS			
Fixed Assets			
Tangible Assets	2.4	0	4,470,308
Non-Current Investments	2.5	-	6,000
		0	4,476,308
CURRENT ASSETS			
Stock-in-Trade		-	-
Other Current Assets	2.6	3,864,951	3,864,951
Cash and Cash Equivalents	2.7	258,979	83,238
Short-term loans and advances	2.8	2,986,462	1,982,324
TOTAL		7,110,392	10,406,821
Significant Accounting Policies and Notes on Accounts	1		
AS PER OUR REPORT OF EVEN DATE			
FOR G. SIVAPRAKASH		For & On behalf of the Board	
CHARTERED ACCOUNTANT			
G.Sivaprakash	B.V.S. KOTESWARA RAO	ANITHA	
PROPRIETOR	DIRECTOR	DIRECTOR	
M. No : 024556			

INDO-AMERICAN ADVANCED PHARMACEUTICALS LTD

STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31st MARCH, 2012

(All amount in Rupees except Share data and unless otherwise stated)

PARTICULARS	Note No.	31.03.2012	31.03.2011
		₹	₹
INCOME			
Revenue from operations		2,078,110	2,403,191
Other Income		NIL	NIL
TOTAL INCOME		2,078,110	2,403,191
EXPENSES			
Changes in Inventories of Finished Goods, Work in Progress & Closing Stock		-	-
Purchase of Stock		-	-
Selling & Other Administrative Expenses		1,882,120	2,478,766
Depreciation Expenses		-	396,281
Finance Cost		-	-
Other expenses		3,366,589	-
TOTAL EXPENSES		5,248,709	2,875,047
PROFIT BEFORE TAXATION		(3,170,599)	(471,856)
Tax Expense:			
Current tax		-	-
Deferred Tax		-	-
NET PROFIT FOR THE YEAR		(3,170,599)	(471,856)
Earnings per equity share:			
Basic and Diluted (Face Value of ₹1/- each, Previous Year ₹1/- each)		(0.84)	(0.13)

Significant Accounting Policies & Notes to Financial Statements

AS PER OUR REPORT OF EVEN DATE

1

**FOR G. SIVAPRAKASH
CHARTERED ACCOUNTANTS**

For & on behalf of the Board

G.Sivaprakash
PROPRIETOR
M. No : 024556

**B.V.S. KOTESWARA RAO L. N. SHARMA
DIRECTOR DIRECTOR**

Place : Chennai
Date : 27th August 2012

INDO-AMERICAN ADVANCED PHARMACEUTICALS LTD
Statement of Cash Flow Annexed to the Balance Sheet as at 31st March, 2012

(In ₹)

	31.03.2012	31.03.2011
A. Cash Flow from Operating Activities		
<i>Net Profit before tax and extraordinary Items</i>	(3,170,599)	(471,856)
<i>Adjustments for</i>		
Depreciation	-	396,281
Dividend	-	-
Miscellaneous Income	-	-
Loss on Sale of Fixed Assets	3,366,589	-
<i>Operating profit before working capital changes</i>	I 195,990	(75,575)
<i>Adjustments for Capital Changes</i>		
Decrease (Increase) in Trade and other Receivables	-	24,785
Decrease (Increase) in Inventories	-	-
Decrease (Increase) in Current Liabilities	(125,830)	(51,692)
Earlier Year Income Tax Adjustments	-	-
<i>Cash Generated from operations</i>	II (125,830)	(26,907)
Net Cash From Operating Activities	I+II 70,160	(102,482)
Taxes (Paid) / Refund Received	III -	-
Cash Flow before Extra-Ordinary Items	I+II+III 70,160	(102,482)
Xtra Ordinary Items	-	-
Net Cash Flow from Operating Activities	(A) 70,160	(102,482)
[I +II+III]		
B. Cash Flow From Investing Activities		
Purchase of Fixed Assets	-	-
Sale of Fixed Assets	1,103,719	-
Decrease / (Increase) in Investments	(998,138)	-
Dividend Received	-	-
Miscellaneous Income	-	-
Net Cash from Investing Activities	B 105,581	-
C. Cash Flow From Financing Activities		
Proceeds from Preferential Issue	-	-
Net Cash used in Financing Activities	C -	-
D Net Increase in Cash & Cash Equivalents	D 175,741	(102,482)
Opening Balance of Cash & Cash Equivalents	83,238	185,720
E Closing Balance of Cash & Cash Equivalents	E 258,979	83,238

For and on behalf of the Board

Chennai, August 27, 2012

Director

Director

FOR G. SIVAPRAKASH

Chartered Accountant

Chennai, August 27, 2012

G.Sivaprakash

PROPRIETOR

Membership No. 024556

INDO-AMERICAN ADVANCED PHARMACEUTICALS LTD

1. SIGNIFICANT ACCOUNTING POLICIES

1.1 Basis of Preparation of Financial Statements

Financial Statements have been prepared under the historical cost convention and in accordance with the provisions of Companies Act, 1956. Accounting Policies not referred to otherwise are consistent and are in accordance with the generally accepted accounting Principles in India.

1.2 Use of Estimates

The preparation of Financial Statements are in conformity with generally accepted accounting principles requires estimates and assumptions to be made to that effect the reported amount of Assets and Liabilities on the date of financial statements and the reported amount of revenue and expenses during the reporting period. Difference between the actual results and estimates are recognized in the period in which the results are known/materialized.

1.3 Fixed Assets

All the Fixed Assets has been sold during the year. Total Asset WDV of Rs. 44,70,308 /- has realised an amount of Rs. 11,03,719 /- and the balance of Rs. 33,66,589/- has been written off in the Profit & Loss A/c

1.4 Depreciation

Since all the Fixed assets has been sold during the year. Hence, Depreciation is N.A

1.5 Investments

Investments which are readily realisable and intended to be held for less than one year are classified as Current Investments. All other Investments are classified as long term investments. Current Investments are carried at lower of cost and fair value determined on an individual investment basis. Long Term investments are carried at cost. Provision for diminution in the value of long tem investments is made only if such a decline is other than temporary in nature in the opinion of the management.

1.6 Inventories

Stock-in-trade has been valued at cost or market price which ever is lower.

1.7 Taxes on Income

No Provision for Taxation has been provided during the year and accordingly the policies are deviation from the Accounting Standards

1.8 Provisions, Contingent Liabilities and Contingent Assets

Provisions involving substantial degree of estimation in measurement are recognized when there is a present obligation as a result of past events and it is probable that there will be an outflow of resources. Contingent Liabilities are not recognized but are disclosed in the Notes. Contingent Assets are neither recognized nor disclosed in the financial statements.

1.9 Revenue Recognition

Items of Income and Expenditure are recognized and accounted for on Accrual basis.

1.10 Contingent Liability, if any, are disclosed by way of Notes.

For and on behalf of the Board

FOR G. SIVAPRAKASH
Chartered Accountant

Director

Director

G.Sivaprakash
Membership No. 024556

INDO-AMERICAN ADVANCED PHARMACEUTICALS LTD

Notes forming part of the Financial Statements for the year ended March 31, 2012

2.1 SHARE CAPITAL

Particulars	31.03.2012		31.03.2011	
	Number	Rs.	Number	Rs.
Authorised				
Equity Shares of 10/- each (Previous Year 10/-)	5,500,000	55,000,000	5,500,000	55,000,000
Issued				
Equity Shares of 10/- each (Previous Year 10/-)	5,009,200	50,092,000	5,009,200	50,092,000
	5,009,200	50,092,000	5,009,200	50,092,000
Subscribed and fully paid up				
Equity Shares of 10/- each (Previous Year 10/-)	2,506,800	25,068,000	2,506,800	25,068,000
	2,506,800	25,068,000	2,506,800	25,068,000
Subscribed but no fully paid up				
Equity Shares of 10/- each 5/- not paid up	2,502,400	12,512,000	2,502,400	12,512,000
	2,502,400	12,512,000	2,502,400	12,512,000
Total	5,009,200	37,580,000	5,009,200	37,580,000

<u>Equity shares with voting rights</u>				
Aggregate of calls unpaid				
- by directors	-	-	-	-
- by officers	-	-	-	-
- by others	2,502,400	12,512,000	2,502,400	12,512,000

NOTES:

a. Equity shareholder holding more than 5% of equity shares along with the number of equity shares held is as given below

V.Koteswara Rao	304500	6.08
B.Bijayalakshmi	315600	6.30
BVS Kiran Kumar	300300	5.99
	920400	

b. The company has one class of Equity shares having a par value of Re. 10/- each. Each shareholder is eligible to one vote per share held.

2.2 RESERVES AND SURPLUS

Particulars	31.03.2012	31.03.2011
	₹	₹
Securities Premium Reserve	-	-
General Reserve		
Opening balance	-	-
Add : Transfer from Surplus	-	-
	-	-
Surplus in Profit & Loss Statement		
Opening balance	(28,699,633)	(28,227,777)
Add: Net Profit for the year	(3,170,599)	(471,856)
Amount available for Appropriations	(31,870,232)	(28,699,633)
Less: Appropriations		
Transfer to Statutory Reserves	-	-
Transfer to Contingent Provision against Standard Assets	-	-
	(31,870,232)	(28,699,633)
Total	-31,870,232	-28,699,633

2.3 OTHER CURRENT LIABILITIES

Particulars	31.03.2012	31.03.2011
	₹	₹
Other payables		
Trade Payables	573,670	573,670
Other Current Liabilities	61,321	187,151
Total	634,991	760,821

2.4 FIXED ASSETS

Tangible Assets	Cost/Book Value as at 1st April 2010	Additions during the year	Sales/ Adjustments during the year	Cost/Book Value as at 31st March 2011	Depreciation on Cost/Book Value as at 1st April 2010	Sales / Adjustments during the year	Depreciation for the year	Depreciation on Cost/Book Value as at 31st March 2012	Balance as at 31st March 2012	Balance as at 31st March 2011
Land	1,156,610	-	-	1,156,610	-	1,156,610	-	-	-	1,156,610
Office Equipment	20,571	-	-	20,571	3,086	17,485	-	-	-	17,485
Dataprocessing Equipment	43,242	-	-	43,242	6,486	36,756	-	-	-	36,756
Building	2,921,774	-	-	2,921,774	292,177	2,629,597	-	-	-	2,629,597
Electrical Equipment	113,652	-	-	113,652	17,048	96,604	-	-	-	96,604
Furniture & Fittings	94,701	-	-	94,701	14,205	80,496	-	-	-	80,496
Vehicles	11,602	-	-	11,602	2,320	9,281	-	-	-	9,281
Fax Machine	3,083	-	-	3,083	462	2,621	-	-	-	2,621
Electrical Typewriter	2,570	-	-	2,570	385	2,184	-	-	-	2,184
Lab Equipment	12,449	-	-	12,449	2,490	9,959	-	-	-	9,959
Machineries	309,652	-	-	309,652	46,448	263,204	-	-	-	263,204
Tata Sumo	15,589	-	-	15,589	3,118	12,471	-	-	-	12,471
Technical Cons. Charges	161,095	-	-	161,095	8,055	153,041	-	-	0	153,041
Total	4,866,589	-	-	4,866,589	396,281	4,470,308	-	-	0	4,470,308

2.5 NON CURRENT INVESTMENTS

Particulars	As at 31/03/2012		As at 31/03/2011	
	Numbers	Amount Rs.	Numbers	Amount Rs.
Long Term Investments (Non-Trade)				
(1) GOVERNMENT SECURITIES	-	-	-	6,000
TOTAL (A)	-	-	-	6,000

2.6 OTHER CURRENT ASSETS

Particulars	31.03.2012	31.03.2011
	₹	₹
Miscellaneous Expenditure Not Written Off	3,864,951	3,864,951
Total	3,864,951	3,864,951

INDO-AMERICAN ADVANCED PHARMACEUTICALS LTD

Notes forming part of the Financial Statements for the year ended March 31, 2012

2.7 CASH AND BANK BALANCES

	31.03.2012	31.03.2011
	₹	₹
Cash and Cash Equivalents		
Cash in Hand		
Kolkata	251,561	75,820
Balances with banks		
Vysya Bank	1,964	1,964
Catholic Syrian Bank - Nlr	1,701	1,701
Catholic Syrian Bank - Chennai	3,753	3,753
Total	258,979	83,238

2.8 SHORT-TERM LOANS & ADVANCES (Unsecured)

Particulars	31.03.2012	31.03.2011
	₹	₹
<u>Considered good</u>		
Trade Receivables	1,065,498	1,065,498
Unsecured Loans	1,500,000	495,862
Telephone Deposits	21,650	21,650
Machinery Advances	165,000	165,000
T.D.S	28,396	28,396
Refund Due - Asst. Year (97-98)	1,090	1,090
Electricity Deposits	53,500	53,500
Sales Tax Deposits	15,000	15,000
Advances to Staff	135,280	135,280
Accrued Interest on Government Securities	1,048	1,048
Total	2,986,462	1,982,324

2.19 Related Parties Disclosures (As per Accounting Standard 18)

1. Relationship

- a. Wholly Owned Company - Not Any
- b. Associate Company - None
- c. Company under the Common Control of Promoters
- d. Key Management Personnel

2. Transactions

There has been no related parties transactions during the year under review except normal share transactions executed through

2.20 Segment Reporting (As per Accounting Standard 17)

a. The Company has three Primary Business Segments viz.

i. Pharmaceutical Business

Gross Segment Revenue

i. Pharmaceutical Business

Current Year

-3,170,599

Previous Year

-471,856

b. Secondary Segment

The Company operates predominantly within the geographical limits of India. It has no secondary segment revenue.

2.21 Disclosure for Payment to Micro, Small & Medium Enterprises

The Company has not received any intimation from their suppliers regarding their status under the Micro, Small and Medium Enterprises Development Act, 2006 and hence disclosure, if any, relating to the amount unpaid as at the year end together with interest paid / payable as required under the said Act, have not been given.

2.22 Impairment of Assets

Company Management during the year have carried out technological evaluation for identification of Assets, if any, in accordance with Accounting Standard 28. Based on the judgement of the Management and as certified by Directors, no provision for impairment is found to be necessary in respect of any Assets as all the assets were sold off during the year

Note : 2.23

The revised Schedule VI has been become effective from 1st April 2011 for the preparation of Financial Statements. This has significantly impacted the disclosure and presentation made in the financial statements. Previous Years' figures have been regrouped/re-classified wherever necessary to the correspond with the current year classifications / disclosures.

Indo-American Advanced Pharmaceuticals Ltd.

No.24,Railway Colony, III Street, Aminjikarai, Chennai- 600 029,Tamilnadu

I/We _____ resident of _____
in the district of _____ being member/members of the above
named Company, hereby appoint _____
resident of _____ in the district of _____
or failing him _____ resident of _____
_____ in the district of _____
_____ as my/our proxy to attend and vote for me/us on my/our behalf at the 20th
Annual General Meeting of the Company to be held on Saturday, the 29th day of September 2012 at
3.30 P.M., at No.24,Railway Colony, III Street, Aminjikarai, Chennai- 600 029,Tamilnadu and any
adjournment thereof.

Registered Folio No./DP-Client ID _____ No. of Shares held _____

Signed on this _____ day of _____ 2012

Signed by the said _____

Signature of Proxy _____

Attested by Shareholder _____

Affix
Revenue
Stamp

✂

Indo-American Advanced Pharmaceuticals Ltd.

No.24,Railway Colony, III Street, Aminjikarai, Chennai- 600 029,Tamilnadu

ATTENDANCE SLIP

I hereby record my presence at the 20th Annual General Meeting of the Company held on Saturday,
the 29th day of September 2012 at 3.30 P.M., at No.24,Railway Colony, III Street, Aminjikarai, Chennai-
600 029,Tamilnadu.

Name of Shareholder/s _____

Father/Husband's Name _____

Name of Proxy or Company Representative _____

Registered Folio No. / DP-Client ID _____ No. of Shares held _____

Signature of the Shareholder(s) or Proxy or Company Representative _____

If Undelivered, Please Return to

INDO-AMERICAN ADVANCED PHARMACEUTICALS LIMITED

No.24, Railway Colony,

III Street, Aminjikarai,

Chennai- 600 029

Tamilnadu, India

Tel : 91- 44 – 4255528.

Email ID : kiranbvs@yahoo.com